NewLimit is at the forefront of biotechnological research focused on innovative therapies for aging-related diseases, particularly by rejuvenating aging cells using epigenetic reprogramming factors. The company's approach integrates functional genomics, pooled perturbation screening, and advanced machine learning models to deeply understand and combat the biology of epigenetic aging and diseases. This intersection of cutting-edge science and dedicated research offers a vibrant, intellectually stimulating work environment that pioneers significant advancements in medicine and healthcare.